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Abstract
Background A feasibility study (n = 19) evaluated the
safety and initial efficacy of transoral incisionless fundo-
plication (TIF) for the treatment of gastroesophageal
disease (GERD). The results at 1 year (n = 17) indicated
that TIF was safe and had a significant effect on reducing
GERD symptoms, proton pump inhibitor (PPI) usage, acid
exposure, and small hiatal hernia. This study was designed
to evaluate the long-term safety and durability of TIF.
Methods Fourteen patients (50% female; median age,
34 years) completed the 2-year follow-up assessment tests.
Three patients were excluded from the study after 1 year
because two of them underwent retreatment and one was
lost to follow-up.
Results At 2 years, no adverse events related to TIF were
reported. A C50% improvement in GERD-HRQL scores
compared with those at baseline on PPIs was sustained by
64% of patients. TIF was effective in eliminating heartburn
in 93% of patients and daily PPI therapy in 71% of patients.
Significantly (p \ 0.05) more patients were able to con-
sume reflux-causing foods and maintain lifestyle activities
without GERD symptoms compared with baseline on PPIs.
Fundoplications were durable and maintained their geo-
metric dimensions. TIF was effective in eliminating hiatal
hernia in 60% of patients and esophagitis in 55% of
patients. Global assessment of all outcomes in each patient
revealed that 79% of patients experienced complete cure
(29%) or remission (50%) of GERD at 2 years after TIF.
Conclusion The results at 2 years supported the long-
term safety and durability of TIF and its sustained effect on
the elimination of heartburn, esophagitis, B2 cm hiatal
hernia, and daily dependence on PPIs.
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An effective treatment for gastroesophageal reflux disease
(GERD) is expected to relieve symptoms, heal esophagitis
(if present), and prevent chronic complications [1–3].
Depending on the stage of the disease, patients are treated
with antisecretory medication (usually a proton pump
inhibitor, PPI) or referred for antireflux surgery (usually
performed laparoscopically) [2]. Short-term gastric acid
suppression with antisecretory medication results in a rapid
remission of symptoms and healing of esophagitis within
4–8 weeks [4–7]. However, 30–40% of patients with
GERD do not respond symptomatically to a standard dose
of PPIs, and 50–75% of patients experience relapse of
symptoms and esophagitis after cessation of treatment
[5, 6, 8, 9]. Patients who are unresponsive to PPIs, show
intolerance to PPIs, have a large hiatal hernia, or prefer not
to take medication long-term are referred for antireflux
surgery [10]. Although antireflux surgery has been shown
to be more effective than PPIs in long-term management of
chronic GERD, patients are reluctant to undergo surgery
because of associated risks and side effects [11–15]. An
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effective endoscopic (transoral) procedure that can cure
reflux without considerable risks and side effects could be a
valid alternative treatment for the 30% of patients with
GERD who do not respond symptomatically to PPIs
and, eventually, undergo laparoscopic procedure within
3–5 years of therapy, and those who are managed suc-
cessfully with PPIs but are unwilling to take daily
medication for the rest of their lives. For those patients
with unmet needs, an earlier endoscopic intervention might
represent the best therapeutic option [1, 16–18].
A novel antireflux transoral incisionless fundoplication
(TIF) using EsophyX (EndoGastric Solutions, Redmond,
WA, USA) was designed to construct an anterior partial
fundoplication of 270 degrees by attaching the fundus to
the anterior and left lateral wall of the distal esophagus
slightly below the esophagogastric junction. Two clinical
trials demonstrated the safety and effectiveness of TIF in
treating patients with chronic GERD at 1 year [19, 20].
This study reports the 2-year follow-up results from the
feasibility study that evaluated the safety and durability
of TIF.
Patients and methods
This single-center feasibility study was conducted accord-
ing to a clinical investigational protocol approved by the
ethics committee at the Centre Hospitalier Universitaire St.
Pierre, Brussels, Belgium [19]. Patients (n = 19) were
enrolled if they had chronic symptomatic GERD lasting
more than 6 months, a small hiatal hernia, were treated
with daily PPI therapy, showed anatomic deterioration of
esophagogastric junction, and signed informed consent.
Patients were excluded if they had a body mass index
(BMI) C30 kg m-2, esophagitis grade D in the Los
Angeles classification [21], irreducible hiatal hernia
[3 cm, esophageal or gastric emptying diseases, or pre-
viously failed antireflux procedures.
Initial screening assessment was conducted without
discontinuation of PPIs and consisted of the nine-question
GERD health-related quality-of-life (GERD-HRQL) [22],
24-hour ambulatory pH-metry [23, 24], upper GI endos-
copy, esophageal biopsy, esophageal manometry, medical
history, and GERD medication usage as described previ-
ously [19, 20]. In addition, we assessed each patient’s
ability to consume foods and beverages commonly asso-
ciated with triggering GERD symptoms, such as citrus,
strawberries, tomatoes, chocolate, fatty foods, deep-fried
foods, spicy foods, carbonated drinks, tea, coffee, caffei-
nated drinks, and alcohol [25]. Patients were asked whether
they were able (‘‘yes’’) or unable (‘‘no’’) to consume each
of the following foods and beverages without symptoms of
GERD. The effect of GERD on lifestyle activities was
assessed by asking patients whether they could eat late at
night, smoke, drink alcohol, or exercise 1 hour after a meal
without GERD symptoms. Dietary and lifestyle changes
were recorded using case report forms (CRFs).
The TIF procedure was performed under general anes-
thesia with nasal or transoral intubation and following the
standard TIF 1 protocol [19, 20, 26]. The device was
inserted transorally into the esophagus with the patient
in the left-lateral position. Hiatal hernia, if present, was
reduced by returning the squamocolumnar junction to its
natural position below the diaphragm using a built-in
vacuum invaginator. During a single insertion, a partial
anterior fundoplication was constructed through retraction
of full-thickness plications and tailored placement of
multiple fasteners circumferentially around the gastro-
esophageal junction starting on the greater curve side of the
valve [19].
The follow-up assessment tests at 2 years consisted of
GERD-HRQL questionnaire, upper GI endoscopy, GERD
medication usage, and questions related to diet and lifestyle
activity changes. The long-term durability of TIFs was
evaluated by comparing their geometric aspects, including
valve length, defined as the length (in centimeters) from the
apex of the fundus to the valve lip [27], circumference,
defined as the distance in degrees between the two most
distant points of esophagogastric valve, as well as Hill
grade [28] and adherence to the endoscope through the
duration of the study using published and unpublished data
from the same study [19]. A global assessment of all out-
come measures was performed for each patient to
determine the long-term effectiveness of TIF in curing
GERD [20]. Patients were considered ‘‘cured’’ if they had
no more heartburn or regurgitation, eliminated esophagitis
and hiatal hernia, and discontinued all usage of PPIs.
Patients were considered ‘‘improved’’ if they had reduced
heartburn, esophagitis, or hiatal hernia and required occa-
sional PPI therapy.
Statistical analysis
Primary endpoint success was C50% improvement
(reduction) in GERD-HRQL scores at 2 years compared
with those at baseline on PPIs. The total GERD-HRQL
scores were calculated by summing the responses to nine
questions [22]. The heartburn score was calculated by
summing the responses to the first six questions. Absent or
rare heartburn (scores B2 to each of the six questions, or
total score B12) was indicative of heartburn elimination.
Patients’ satisfaction with their health condition was eval-
uated based on question 10: ‘‘very satisfied,’’ ‘‘satisfied,’’
‘‘neutral,’’ or ‘‘dissatisfied.’’ Because of nonsymmetrical
data distributions, p values for changes from baseline to
2 years for GERD-HRQL scores were calculated by using
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the Mann–Whitney test (College Station, PA, USA). Sec-
ondary endpoint success was a total cessation of PPIs,
hiatal hernia elimination, and esophagitis healing. Patients
taking PPIs between the 1- and 2-year visits were excluded
from calculations of esophagitis healing rate to avoid type
1 error, because the usage of medication represented a
confounding variable to the effect of TIF on esophagitis
improvement. The frequency of ‘‘yes’’ and ‘‘no’’ responses
to questions related to symptoms, dietary and lifestyle
activity changes was tested for significance using Spear-
man’s rank correlation followed by the Mann–Whitney
test. Patients who did not smoke, exercise, or drink alcohol
were excluded from the analysis of these activities. Dura-
bility of TIF restoration was assessed by comparing TIF
length and circumference during the duration of the study
using the Mann–Whitney test. Values with p \ 0.05 were
considered significant for all tests.
Results
Patient characteristics
Fourteen of 17 patients completed the 2-year follow-up
assessment. Two of the remaining patients underwent re-
treatment and one was lost to follow-up. They were
excluded from the analysis at 2 years because of the lack of
data. Patient 001 and 003 underwent retreatment after
1 year with laparoscopic Nissen and TIF2 procedure,
respectively, because they continued to experience symp-
toms and required daily PPIs [19]. The retreated patients
were considered failures per intent-to-treat analysis and
omitted from analysis of efficacy data per protocol. The
third patient (008) was lost to follow-up at 2 years because
of the lack of contact.
Patients (n = 14, 50% female) available at 2 years had a
median age of 34 (range, 23–55) years and a median BMI
of 22 (18–31) kg/m2. Patients had suffered from GERD for
a median of 10 (range, 3–15) years and were on continuous
daily PPI therapy for a median of 6 (range, 2–13) years
before undergoing TIF. Median GERD-HRQL score was
17 (range, 12–31) at baseline on PPIs. Upper GI endoscopy
at baseline showed evidence of loose adherence of the
esophagogastric junction and reflux esophagitis in all
patients. A sliding hiatal hernia with 2 cm (n = 7) or 3 cm
(n = 3) in length was demonstrated endoscopically in ten
(71%) patients.
The median follow-up period was 25 (range, 24–27)
months. No adverse events related to the TIF procedure
occurred between the 1- and 2-year follow-up visits. Based
on the answers to questions 7–9 of the GERD-HRQL
questionnaire, daily difficulty in swallowing without pain
was reported by one patient, and daily bloating or gassy
feelings were reported by seven patients. The prevalence of
these symptoms did not differ significantly compared with
baseline on PPIs: 1 (7%) and 8 (57%; p = 0.6) in both
cases.
At 2 years, GERD-HRQL scores improved significantly
(p = 0.004) by a median of 59% compared with baseline on
PPIs (7 vs. 17), and a clinically significant improvement of
scores was demonstrated in nine (64%) patients (Table 1).
Heartburn scores ranged from 0 to 13 at 2 years compared
with 12 and 31 at baseline on PPIs. Scores B12 indicative
of heartburn elimination were reported by 13 (93%)
patients. A total of 86% of patients were satisfied with the
outcomes of the TIF procedure and only one patient was
dissatisfied. Discontinuation of daily PPI therapy was
sustained in ten (71%) patients.
Analysis of dietary changes indicated that significantly
more patients were able to consume citrus (p = 0.049),
deep-fried foods (p = 0.018), spicy foods (p = 0.001),
carbonated drinks (p = 0.006), coffee (p = 0.001), caffe-
inated drinks (p = 0.043), and alcohol (p = 0.002) without
GERD symptoms at 2 years compared with baseline on
PPIs (Fig. 1). Analysis of lifestyle changes indicated that
significantly more patients were able to eat late at night
(p = 0.022), exercise (p \ 0.001), smoke (p = 0.027), and
drink alcohol (p = 0.001) compared with screening on
PPIs.
Upper GI endoscopy revealed that the EsophyX-created
fundoplications had a median length of 3 cm, circumfer-
ence of 200 degrees, tight or moderate adherence, and Hill
grade 1 or 2 (Figs. 2–3; Table 2). Hiatal hernia was elim-
inated in 60% of patients and reduced in an additional 20%
of patients. A hiatal hernia of 2 cm was newly revealed in
one patient. Esophagitis was eliminated in 55% of patients
without taking daily PPIs but remained unchanged in
five patients who had TIF with loose (n = 3) or moderate
(n = 2) adherence (Fig. 4; Table 2). The median TIF
length at 2 years was 27% lower than that measured at the
time of procedure and 0.5 cm less than that measured at
3 months. There was no significant difference between the
median length at 2 years and that at 3 months (p = 0.2),
6 months (p = 0.2), and 12 months (p = 0.6; Fig. 5). The
median TIF circumference at 2 years was 14% lower than
that measured at the time of procedure and 10 degrees less
than that measured at 3 months. There was no significant
difference between the median circumference at 2 years
and that at 3 months (p = 0.6), 6 months (p = 0.3), and
12 months (p = 0.2; Fig. 6).
Global assessment revealed that 79% of patients expe-
rienced complete cure (29%) or remission (50%) of GERD
at 2 years after TIF. The cured patients had no more
heartburn, esophagitis, and hiatal hernia (Table 2) and
those in remission experienced an elimination of heartburn
and reduction of their hiatal hernia or esophagitis. The
Surg Endosc (2009) 23:957–964 959
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remaining 21% of patients, with ongoing GERD, continued
to experience heartburn and required daily PPI therapy.
Comparison of the scores did not reveal any significant
differences between the successful patients who were cured
or in remission of GERD and those with ongoing GERD.
Among cured patients (004, 006, 012, and 014), most had
normal pH scores before the procedure while taking PPIs
(004, 006, and 012) and also at 1 year while not taking
PPIs (004, 006, and 014). Among seven patients who were
in remission, normal pH scores were reported in 012 and
018 before the procedure while taking PPIs, in 007 and 015
at 1 year while not taking PPIs, and in 005 and 016 during
both periods. Similarly, among three unsuccessful patients
(002, 010, and 017) who had ongoing GERD and required
daily PPIs, two had normal pH scores before the procedure
while taking PPIs and at 2 years (002 and 010). The two
retreated patients (001 and 003) also had normal pH scores
before TIF while taking PPIs and pathologic pH at 1 year.
Discussion
The study population consisted of patients with advanced
stages of chronic GERD who are typically referred for
surgery [10, 29, 30]. The patients had suffered from the
disease for more than 10 years and had continuous daily
Table 1 GERD-HRQL scores and PPI usage at 2 years after transoral incisionless fundoplication (TIF)











002 15 16 -7 15 13 Satisfied Daily
004 16 1 94 12 0 Very satisfied None
005 14 13 7 13 12 Very satisfied None
006 16 1 94 16 1 Very satisfied None
007 21 9 57 19 8 Satisfied None
009 12 7 42 12 7 Satisfied None
010 23 20 13 20 11 Unsatisfied Daily
012 16 6 63 13 5 Satisfied None
013 27 2 93 22 2 Very satisfied None
014 17 4 76 13 4 Very satisfied None
015 25 6 76 19 5 Satisfied None
016 21 9 57 15 9 Satisfied Occasional
017 31 16 48 26 12 Neutral Daily
018 15 6 60 15 6 Satisfied None
n = 14
Median (range) 17 (12–31) 7 (1–20) 59 (-7 to 94) 15 (12–26) 7 (0–13)
p = 0.004
n (%) Improvedb Eliminatedc Eliminatedc Satisfied 12 (86%) None
9 (64%) 2 (14%) 13 (93%) Unsatisfied 1 (7%) 10 (71%)
Neutral 1 (7%)
a Positive values indicate improvement (reduction) in the scores
b Defined by clinically significant reduction of scores C50% compared with baseline taking PPIs
c Defined by heartburn scores B12 with B2 (rare) scores per each of six questions
Fig. 1 Percentage of patients who were able to consume foods and
beverages without GERD symptoms 2 years after transoral incision-
less fundoplication (TIF) while not taking PPIs (blue field) compared
with before TIF while taking PPIs (purple field). Significant
differences indicated by *if p \ 0.05, or **if p \ 0.01
960 Surg Endosc (2009) 23:957–964
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PPI therapy for more than 6 years before undergoing the
TIF procedure. Despite having daily PPI therapy, patients
continued to suffer from daily heartburn and esophagitis.
Such a high prevalence of esophagitis was indicative of
prolonged dysfunctionality of the antireflux barrier result-
ing, most likely, from anatomic deterioration of the
esophagogastric junctions in those patients. Upper GI
endoscopy revealed that the esophagogastric junctions in
all patients had loose adherence and 59% of patients had a
2- to 3-cm hiatal hernia. Complete control of reflux in this
population of patients could only be achieved through an-
tireflux surgery, which has been shown more effective than
PPIs in terms of patient satisfaction and clinical outcome
because of its ability to reconstruct the biomechanics and
physiology of the esophagogastric junction [11–14, 27, 31].
It is foreseeable that this population of patients with
chronic GERD requiring long-term medical therapy would
benefit from early surgery, which has been demonstrated in
several randomized, controlled trials [15, 30, 32].
The absence of TIF-related adverse events supported
long-term safety of TIF. Although gas bloating and gassy
feelings were experienced daily by 50% of patients, they
were not more frequent than while patients were under-
going PPI therapy. The gas bloating after antireflux surgery
often is associated with dysphagia and the inability of
patients to belch or vent after ‘‘well-constructed’’ fundo-
plication [10]. In general, partial (180–270-degree)
fundoplication is associated with less dysphagia and gas-
related side effects than a full fundoplication [33, 34]. The
‘‘tailored,’’ ‘‘transoral,’’ and ‘‘incisionless’’ nature of the
TIF procedure using EsophyX is at the basis of its low
invasiveness, which has been supported by few, mild, and
transient postoperative side effects and the absence of long-
term side effects as reported in the current article [19, 20].
The TIF procedure appeared to be more effective than
PPIs in controlling symptoms in 64% of patients whose
GERD-HRQL scores at 2 years were at least 50% better
than those at baseline on PPIs. Moreover, TIF achieved an
effective control of heartburn in 93% of patients and
resulted in complete elimination of the need for antise-
cretory medication in 71% of patients. Heartburn is the
most prevalent and troublesome symptom of GERD, and
its elimination has been associated with improved wellbe-
ing of patients [35–37]. The effective elimination of
heartburn and increased dietary choices and lifestyle
activities sustained higher patient’s satisfaction with the
TIF procedure. These initial long-term results suggested
that patients experienced a sustained higher quality of life
after TIF than they had on PPI therapy.
The maintenance of the geometric aspects and tight-to-
moderate adherence of the fundoplications in the majority
of patients during 2 years was supportive of the long-term
durability of TIF. The 27% and 14% decrease during
2 years in the median length and circumference, respec-
tively, could have been overestimated by the presence
of edema at the time of intraoperative measurements.
Fig. 2 Endoscopic retroflexed
images of the esophagogastric
junctions in patient 009 (top)
and 016 (bottom) before (left)
and 2 years after (right)
transoral incisionless
fundoplication
Surg Endosc (2009) 23:957–964 961
123







Hiatal hernia (cm) Esophagitis (grade) Curedc In
remissiond
Ongoinge
Beforea 1 yra 2 yr Beforea 1yra 2 yr
002 3 210 Moderate/2 2 0 0 A A Noneb – – Yes
004 4 210 Moderate/2 0 0 0 C A None Yes – –
005 3 230 Moderate/3 3 0 0 C A C – Yes –
006 4 200 Tight/1 0 0 0 A None None Yes – –
007 3 180 Loose/3 2 2 0 A A A – Yes –
009 3 200 Moderate/2 2 0 2 A B None – Yes –
010 3 180 Moderate/2 2 2 0 A A Noneb – – Yes
012 3 180 Moderate/2 2 0 0 A None None Yes – –
013 3 210 Moderate/2 2 2 2 A A A – Yes –
014 4 200 Tight/1 0 0 0 A A None Yes – –
015 3 90 Loose/3 3 2 1 A B A – Yes –
016 4 210 Moderate/1 0 0 2 A None None – Yes –
017 3 180 Loose/3 3 2 0 B Bb Ab – – Yes




3 (2–4) 200 (90–230)
n (%) C3 cm C180 degree CModerate Eliminated Eliminatedb 4 (29%) 7 (50%)
3 (21%)










a Values from Cadie`re et al (2008) [19]
b Patients on daily PPIs were excluded from calculations
c Cured patients had no more heartburn, PPI daily dependence, hiatal hernia and esophagitis at 2 years [20]
d In remission patients had reduced heartburn, hiatal hernia or esophagitis but required occasional usage of PPIs [20]
e Patients with ongoing GERD had heartburn, hiatal hernia or esophagitis, and required daily PPIs [20]
Fig. 4 Prevalence of esophagitis before and during a 2-year period
after the transoral incisionless fundoplication procedure. Grades
according to the Los Angeles classification [21]
Fig. 3 Adherence of transoral incisionless fundoplications through 2-
year duration of the study
962 Surg Endosc (2009) 23:957–964
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Therefore, if we take the measurements without edema at
3 months, the decrease of 0.5 cm and 10 degrees during
the ensuing 2 years was small and not significant. More-
over, the elimination of small hiatal hernia in 60% of
patients was durable and effective in sustaining the anti-
reflux functions of TIF and promoted a 55% higher healing
rate of esophagitis than on PPIs. EsophyX continues to be
the only transoral device that is capable of reducing small
hiatal hernia [17]. Because the healing of esophagitis
requires reduced acid exposure, the progression of healing
in those patients who had normal pH at 1 year could be an
objective indication of a sustained and effective reflux
control by TIF.
Although the presented 2-year results were encouraging,
they had a limited value for generalization because of the
small study population and the exclusion of patients who
required retreatment. A multicenter study is currently
underway to evaluate the long-term efficacy of TIF in
eliminating symptoms and normalizing acid exposure.
Disclosure The results were presented in part at the OESO 9th
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